Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effectiveness of Coconut Oil Pulling and Moringa Mouthwash Versus Chlorhexidine in Reducing Gingivitis in Diabetic Children

12. september 2026 oppdatert av: Amira Yehia Zakaria

Effectiveness of Coconut Oil Pulling and Moringa Mouthwash Versus Chlorhexidine in Reducing Gingivitis in Diabetic Children: A Randomized Controlled Pilot Study

Gingivitis is a common and reversible inflammatory condition, mainly caused by dental plaque, and is particularly prevalent among children. Children with diabetes mellitus are more susceptible because of altered immune responses, impaired healing, and changes in the oral microbiota.

Although mechanical plaque control is the primary method of prevention, poor oral-hygiene compliance in children highlights the need for safe adjunctive treatments. Chlorhexidine, while highly effective, can cause staining, taste alteration, and mucosal irritation, limiting its long-term pediatric use.

Natural alternatives such as coconut oil and Moringa oleifera have attracted attention because of their antimicrobial, anti-inflammatory, and antioxidant properties. Coconut oil, particularly its lauric acid content, may reduce oral pathogens, plaque, and gingival inflammation. Moringa contains bioactive compounds such as flavonoids, phenolic acids, and isothiocyanates that may help reduce inflammation, oxidative stress, and microbial load.

However, comparative clinical evidence on coconut oil versus Moringa for managing gingivitis in diabetic children remains limited, highlighting the need for further clinical research to determine their safety and effectiveness in this vulnerable population.

Studieoversikt

Detaljert beskrivelse

Gingivitis represents one of the most prevalent inflammatory diseases affecting the gingival tissues and remains a major public health concern worldwide, particularly among pediatric populations. It is primarily induced by dental plaque biofilm accumulation along the gingival margin, resulting in gingival inflammation characterized by redness, swelling, bleeding on probing, and discomfort. Although gingivitis is considered a reversible condition, if left untreated, it may progress to periodontitis, leading to irreversible destruction of periodontal supporting structures and eventual tooth loss.

Children with systemic conditions, especially diabetes mellitus, exhibit a higher susceptibility to gingival inflammation due to altered immune responses, impaired wound healing, and changes in oral microbial flora.

Mechanical plaque control through tooth brushing and professional prophylaxis remains the cornerstone of gingivitis prevention and management. However, compliance with routine oral hygiene practices among children is often suboptimal. Therefore, adjunctive therapeutic agents with antimicrobial and anti-inflammatory properties have gained increasing attention. Chlorhexidine mouthwash is widely considered the gold standard chemical plaque control agent; nevertheless, its long-term use is associated with adverse effects including tooth staining, taste alteration, and mucosal irritation, limiting its acceptability among pediatric patients. This has led to growing interest in exploring natural and herbal alternatives that are safe, cost-effective, and well tolerated.Coconut oil has recently gained popularity as a natural oral health agent, particularly through the practice of oil pulling, which is a traditional Ayurvedic technique involving swishing oil in the oral cavity. Coconut oil contains a high concentration of medium-chain fatty acids, predominantly lauric acid, which possesses potent antimicrobial, anti-inflammatory, and antioxidant properties. Lauric acid has demonstrated effectiveness against various oral pathogens, including Streptococcus mutans and Candida species, by disrupting microbial cell membranes and inhibiting biofilm formation. Additionally, coconut oil may reduce gingival inflammation by modulating inflammatory mediators and enhancing tissue healing. Several clinical studies have reported improvements in plaque and gingival indices following coconut oil use, suggesting its potential as a safe adjunctive therapy in managing gingivitis.

Moringa oleifera, commonly referred to as the "miracle tree," is another herbal product that has gained considerable attention for its medicinal and nutritional benefits. It is rich in bioactive compounds including flavonoids, phenolic acids, vitamins, minerals, and essential amino acids. Moringa extracts exhibit strong antimicrobial activity against a broad spectrum of oral microorganisms and possess significant anti-inflammatory and antioxidant effects. These properties are primarily attributed to phytochemicals such as quercetin, chlorogenic acid, and isothiocyanates, which reduce oxidative stress and suppress inflammatory pathways. Recent experimental and clinical studies have suggested that moringa-based formulations may improve periodontal health by reducing plaque accumulation, gingival inflammation, and microbial load, making it a promising natural therapeutic agent.

Despite the documented therapeutic potential of coconut oil and moringa individually, comparative clinical studies evaluating their effectiveness in reducing gingivitis, particularly among diabetic children, remain limited. Pediatric diabetic patients constitute a vulnerable group requiring safe, well-tolerated, and effective adjunctive oral health interventions. Natural herbal agents such as coconut oil and moringa may provide affordable and culturally acceptable alternatives, especially in developing countries where access to conventional dental care may be limited.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Cairo,Egypt
      • Cairo, Cairo,Egypt, Egypt, 11511
        • Faculty of Dentistry Cairo University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Age from 6 to 12 years.
  • Both males and females.
  • Diabetic Children with mild to moderate gingivitis.
  • Medically stable, without other systemic conditions affecting oral health.
  • Written informed consent obtained from parents or legal guardians and assent from the child.

Exclusion Criteria:

  • Severe gingival or periodontal disease
  • Hypersensitivity or allergy to coconut oil, moringa, chlorhexidine, or any component of the study interventions.
  • Presence of systemic conditions other than diabetes that may affect results
  • Antibiotics use, corticosteroids, that may influence gingival health within the past 4 weeks.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Moringa olfera mouthwash
Children will swish aqueous extract preparation from moringa leaves for 1 minute daily for 4 weeks
Active comparator
Eksperimentell: Coconut oil pulling
Oil pulling with 5 mL of virgin coconut oil will be used for swishing for 1 minute once daily under parental supervision.
Active comparator
Aktiv komparator: Chlorhexidine mouthwash
0.12% chlorhexidine mouthwash will be used for Swishing for 1 minute once daily for 4 weeks
Intervetion
Intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gingival Health
Tidsramme: baseline before treatment, immediately after, after 2 weeks and after 4 weeks.
Clinical examination using the Gingival Index
baseline before treatment, immediately after, after 2 weeks and after 4 weeks.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Porphyromonas gingivalis count
Tidsramme: baseline before treatment, immediately after, after 2 weeks and after 4 weeks.
Microbiological analysis manual colony counting
baseline before treatment, immediately after, after 2 weeks and after 4 weeks.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient Acceptability
Tidsramme: baseline before treatment, immediately after, after 2 weeks and after 4 weeks.
5-point Likert scale questionnaire
baseline before treatment, immediately after, after 2 weeks and after 4 weeks.
Patient compliance
Tidsramme: on week 2 and week 4
self-reported adherence using the Modified Morisky Medication Adherence Scale
on week 2 and week 4

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. oktober 2026

Primær fullføring (Antatt)

1. november 2026

Studiet fullført (Antatt)

1. november 2026

Datoer for studieregistrering

Først innsendt

12. september 2026

Først innsendt som oppfylte QC-kriteriene

12. september 2026

Først lagt ut (Faktiske)

17. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Gingivitis reducing mouthwash

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

supporting information

IPD-delingstidsramme

4 weeks

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Studiedata/dokumenter

  1. Studieprotokoll
    Informasjonsidentifikator: Protocol

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere